Eli Lilly and Company (LLY) Earnings History
Elite Compounder37 years of earnings data (1989–2025) · 5-year EPS CAGR exceeds 18% — top-tier earnings quality
Loading earnings history...
Eli Lilly and Company (LLY) Earnings Overview
As of June 21, 2026, Eli Lilly and Company (LLY) reported trailing twelve-month net income of $25.27B, reflecting +96.0% year-over-year growth. The company earned $28.21 per diluted share over the past four quarters, with a net profit margin of 31.7%.
Looking at the long-term picture, LLY's 5-year EPS compound annual growth rate (CAGR) stands at +28.8%, indicating exceptional earnings growth. The company achieved its highest annual net income of $20.64B in fiscal 2025, representing a new all-time high.
Eli Lilly and Company maintains industry-leading profitability with a gross margin of 83.8%, operating margin of 45.6%, and net margin of 31.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including NVO ($121.96B net income, 33.1% margin), PFE ($7.49B net income, 12.4% margin), MRK ($18.25B net income, 28.1% margin), LLY has room to improve margins relative to the peer group. Compare LLY vs NVO →
LLY Earnings vs Peers
Earnings metrics vs comparable public companies
LLY Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $20.64B | +94.9% | $29.70B | $22.95 | 31.7% | 45.6% |
| 2024 | $10.59B | +102.1% | $17.50B | $11.71 | 23.5% | 38.9% |
| 2023 | $5.24B | -16.1% | $10.79B | $5.80 | 15.4% | 31.6% |
| 2022 | $6.24B | +11.9% | $8.65B | $6.57 | 21.9% | 30.3% |
| 2021 | $5.58B | -9.9% | $7.93B | $5.85 | 19.7% | 28.0% |
| 2020 | $6.19B | -25.5% | $7.21B | $6.47 | 25.2% | 29.4% |
| 2019 | $8.32B | +157.4% | $6.00B | $8.69 | 37.3% | 26.9% |
| 2018 | $3.23B | +1683.5% | $6.03B | $3.13 | 15.0% | 28.0% |
| 2017 | -$204M | -107.5% | $4.25B | $-0.19 | -1.0% | 21.3% |
| 2016 | $2.74B | +13.7% | $3.87B | $2.49 | 12.9% | 18.2% |
| 2015 | $2.41B | +0.7% | $3.59B | $2.18 | 12.1% | 18.0% |
| 2014 | $2.39B | -49.0% | $3.33B | $2.15 | 12.2% | 17.0% |
| 2013 | $4.68B | +14.6% | $5.55B | $4.19 | 20.3% | 24.0% |
| 2012 | $4.09B | -6.0% | $5.02B | $3.57 | 18.1% | 22.2% |
| 2011 | $4.35B | -14.2% | $6.32B | $3.90 | 17.9% | 26.0% |
| 2010 | $5.07B | +17.1% | $6.77B | $4.58 | 22.0% | 29.3% |
| 2009 | $4.33B | +308.9% | $6.37B | $3.94 | 19.8% | 29.2% |
| 2008 | -$2.07B | -170.2% | $5.53B | $-1.89 | -10.2% | 27.1% |
| 2007 | $2.95B | +10.9% | $4.80B | $2.71 | 15.8% | 25.8% |
| 2006 | $2.66B | +34.5% | $4.13B | $2.45 | 17.0% | 26.3% |
| 2005 | $1.98B | +9.4% | $3.65B | $1.81 | 13.5% | 24.9% |
| 2004 | $1.81B | -29.3% | $3.66B | $1.66 | 13.1% | 26.4% |
| 2003 | $2.56B | -5.4% | $3.50B | $2.37 | 20.4% | 27.8% |
| 2002 | $2.71B | -2.6% | $3.33B | $2.50 | 24.4% | 30.0% |
| 2001 | $2.78B | -9.1% | $3.73B | $2.55 | 24.1% | 32.3% |
| 2000 | $3.06B | +12.4% | $3.56B | $2.79 | 28.2% | 32.8% |
| 1999 | $2.72B | +29.7% | $3.36B | $2.46 | 27.2% | 33.6% |
| 1998 | $2.10B | +644.8% | $2.82B | $1.87 | 22.7% | 30.6% |
| 1997 | -$385M | -125.3% | $2.44B | $-0.34 | -4.8% | 30.5% |
| 1996 | $1.52B | -33.5% | $2.04B | $1.36 | 21.8% | 29.2% |
| 1995 | $2.29B | +78.1% | $1.98B | $2.02 | 33.9% | 29.3% |
| 1994 | $1.29B | +167.8% | $1.79B | $1.11 | 22.5% | 31.4% |
| 1993 | $480M | -32.2% | $653M | $0.40 | 7.4% | 10.1% |
| 1992 | $709M | -46.1% | $1.16B | $0.61 | 11.5% | 18.7% |
| 1991 | $1.31B | +16.6% | $1.77B | $1.13 | 23.0% | 30.9% |
| 1990 | $1.13B | +20.0% | $1.54B | $0.98 | 21.7% | 29.7% |
| 1989 | $940M | - | $1.16B | $0.80 | 22.5% | 27.9% |
Download Data
Export LLY earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into LLY consensus models and risk factors.
Should I Buy LLY?
Wall Street verdict, signals, and target summaries.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LLY — Frequently Asked Questions
Quick answers to the most common questions about buying LLY stock.
What is LLY earnings per share (EPS)?
LLY trailing twelve-month (TTM) diluted EPS is $28.21, reflecting +96.0% year-over-year growth. The 5-year EPS CAGR is +28.8%. Complete EPS history from 1989 to 2025 is available in the table on this page.
What is Eli Lilly and Company's net income?
Eli Lilly and Company (LLY) trailing twelve-month net income is $25.3B as of 2025. Earnings grew +96.0% year-over-year. Eli Lilly and Company has been profitable for 8 consecutive years.
Is LLY profitable?
Yes, LLY is profitable with a TTM net income of $25.3B and a net profit margin of +31.7%. Eli Lilly and Company has generated profits for 8 consecutive years.
What is LLY's earnings growth rate?
LLY compound annual EPS growth rates (CAGR): 1-Year: +96.0%, 3-Year: +51.7%, 5-Year: +28.8%, 10-Year: +26.5%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2025.
What are LLY's profit margins?
Eli Lilly and Company net profit margin is +31.7%, operating margin is +45.6%, and gross margin is +83.8%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +101.2%.
Is LLY growing earnings?
Yes, LLY earnings are accelerating — EPS growth of +96.0% exceeds the 5-year CAGR of +28.8%. TTM net income reached $25.3B. Earnings momentum is strengthening.
What was LLY's best earnings year?
Eli Lilly and Company's highest annual net income on record is $20.6B, achieved in fiscal year 2025. Earnings history on this page spans 1989 to 2025 and includes all annual and quarterly figures.
What were LLY's earnings last quarter?
LLY's most recent reported quarter was Q1 2026. Net income was $7.4B with diluted EPS of $8.26. For a full breakdown of all quarters, see the quarterly earnings table on this page.